Ligand Pharmaceuticals (LGND) reported adjusted income of $1.55 per share on $ …
SELL SHORT Disclosure: I am/we are short LGND. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
That creates more demand for the stock, which pushes it higher, which forces more shorts to buy the shares and so on and so on. Look at Ligand Pharmaceuticals Inc. (NASDAQ:LGND). The stock has had a big run this year, especially …
The decrease was mainly due to a reduction in bonus and stock compensation. Infinity reaffirmed its outlook ... from the same space worth considering are …
LGND) are all expected to be lower after their earnings are released Thursday. The movement of stock prices in the …
Lemelson Capital chief investment officer Emmanuel Lemelson recently increased his short position in Ligand Pharmaceuticals (NYSE: LGND) after its second quarter earnings report. “Any company whose EPS is down 76 …
Ligand Pharmaceuticals Inc. (LGND) reported second quarter EPS of $0.67 after the bell Monday, up from $0.35 in the prior year period. Ligand Pharmaceuticals gapped open higher Tuesday and spiked to the upside in early trade. The stock …
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals LGND, Enanta Pharmaceuticals ... with an average beat of …
Verastem, Inc. Price and Consensus Verastem, Inc. Price and Consensus | Verastem, Inc. Quote Investors interested in the Medical - Biomedical and Genetics industry may consider a better ranked stock Ligand Pharmaceuticals …
A few better-ranked stocks from the same space worth considering are Ligand Pharmaceuticals LGND, and Enanta Pharmaceuticals ... with an average beat of …